Literature DB >> 34152837

Improving Outcomes in Children With High-Risk Neuroblastoma: The Role of Randomized Trials.

Steven G DuBois1, Rochelle Bagatell2.   

Abstract

Entities:  

Mesh:

Year:  2021        PMID: 34152837      PMCID: PMC8330963          DOI: 10.1200/JCO.21.01066

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   50.717


× No keyword cloud information.
  14 in total

1.  Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma.

Authors:  Brian H Kushner; Kim Kramer; Michael P LaQuaglia; Shakeel Modak; Karima Yataghene; Nai-Kong V Cheung
Journal:  J Clin Oncol       Date:  2004-12-15       Impact factor: 44.544

2.  Response to N7 induction chemotherapy in children more than one year of age diagnosed with metastatic neuroblastoma treated in UKCCSG centers.

Authors:  J A Kohler; C Ellershaw; D Machin
Journal:  Pediatr Blood Cancer       Date:  2007-09       Impact factor: 3.167

3.  Predictors of differential response to induction therapy in high-risk neuroblastoma: A report from the Children's Oncology Group (COG).

Authors:  Navin Pinto; Arlene Naranjo; Emily Hibbitts; Susan G Kreissman; M Meaghan Granger; Meredith S Irwin; Rochelle Bagatell; Wendy B London; Emily G Greengard; Julie R Park; Steven G DuBois
Journal:  Eur J Cancer       Date:  2019-04-01       Impact factor: 9.162

4.  Results of induction chemotherapy in children older than 1 year with a stage 4 neuroblastoma treated with the NB 97 French Society of Pediatric Oncology (SFOP) protocol.

Authors:  Dominique Valteau-Couanet; Jean Michon; Andrée Boneu; Chantal Rodary; Yves Perel; Christophe Bergeron; Hervé Rubie; Carole Coze; Dominique Plantaz; Frédéric Bernard; Pascal Chastagner; Jeannine Bouzy; Olivier Hartmann
Journal:  J Clin Oncol       Date:  2005-01-20       Impact factor: 44.544

5.  Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma: A Randomized Clinical Trial.

Authors:  Julie R Park; Susan G Kreissman; Wendy B London; Arlene Naranjo; Susan Lerner Cohn; Michael D Hogarty; Sheena C Tenney; Daphne Haas-Kogan; Peter John Shaw; Jacqueline M Kraveka; Stephen S Roberts; James Duncan Geiger; John J Doski; Stephan D Voss; John M Maris; Stephan A Grupp; Lisa Diller
Journal:  JAMA       Date:  2019-08-27       Impact factor: 56.272

6.  Impact of MYCN status on response of high-risk neuroblastoma to neoadjuvant chemotherapy.

Authors:  David Yanishevski; M Beth McCarville; Mikhail Doubrovin; Hannah R Spiegl; Xiwen Zhao; Zhaohua Lu; Sara M Federico; Wayne L Furman; Andrew J Murphy; Andrew M Davidoff
Journal:  J Pediatr Surg       Date:  2019-10-25       Impact factor: 2.545

7.  A mechanistic classification of clinical phenotypes in neuroblastoma.

Authors:  Sandra Ackermann; Maria Cartolano; Barbara Hero; Anne Welte; Yvonne Kahlert; Andrea Roderwieser; Christoph Bartenhagen; Esther Walter; Judith Gecht; Laura Kerschke; Ruth Volland; Roopika Menon; Johannes M Heuckmann; Moritz Gartlgruber; Sabine Hartlieb; Kai-Oliver Henrich; Konstantin Okonechnikov; Janine Altmüller; Peter Nürnberg; Steve Lefever; Bram de Wilde; Frederik Sand; Fakhera Ikram; Carolina Rosswog; Janina Fischer; Jessica Theissen; Falk Hertwig; Aatur D Singhi; Thorsten Simon; Wenzel Vogel; Sven Perner; Barbara Krug; Matthias Schmidt; Sven Rahmann; Viktor Achter; Ulrich Lang; Christian Vokuhl; Monika Ortmann; Reinhard Büttner; Angelika Eggert; Frank Speleman; Roderick J O'Sullivan; Roman K Thomas; Frank Berthold; Jo Vandesompele; Alexander Schramm; Frank Westermann; Johannes H Schulte; Martin Peifer; Matthias Fischer
Journal:  Science       Date:  2018-12-07       Impact factor: 47.728

8.  Telomere Maintenance Mechanisms Define Clinical Outcome in High-Risk Neuroblastoma.

Authors:  Balakrishna Koneru; Gonzalo Lopez; Ahsan Farooqi; Karina L Conkrite; Thinh H Nguyen; Shawn J Macha; Apexa Modi; Jo Lynne Rokita; Eduardo Urias; Ashly Hindle; Heather Davidson; Kristyn Mccoy; Jonas Nance; Vanda Yazdani; Meredith S Irwin; Shengping Yang; David A Wheeler; John M Maris; Sharon J Diskin; C Patrick Reynolds
Journal:  Cancer Res       Date:  2020-04-14       Impact factor: 12.701

9.  Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial.

Authors:  Susan G Kreissman; Robert C Seeger; Katherine K Matthay; Wendy B London; Richard Sposto; Stephan A Grupp; Daphne A Haas-Kogan; Michael P Laquaglia; Alice L Yu; Lisa Diller; Allen Buxton; Julie R Park; Susan L Cohn; John M Maris; C Patrick Reynolds; Judith G Villablanca
Journal:  Lancet Oncol       Date:  2013-07-25       Impact factor: 41.316

10.  High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial.

Authors:  Andrew D J Pearson; C Ross Pinkerton; Ian J Lewis; John Imeson; Caroline Ellershaw; David Machin
Journal:  Lancet Oncol       Date:  2008-03       Impact factor: 41.316

View more
  1 in total

1.  Effects of Surgery Combined with Different Chemotherapy on Matrix Metalloproteinase-9 and Tissue Inhibitors of Metalloproteinase-1 in Children with Neuroblastoma.

Authors:  Zilong Qi; Xinning Wang; Liang Yin; Kun Ma; Lei Chen; Jinmin Li
Journal:  J Oncol       Date:  2022-07-05       Impact factor: 4.501

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.